Vertex Pharmaceuticals (VRTX) Free Cash Flow Growth (3y) (2012 - 2026)
Vertex Pharmaceuticals (VRTX) Free Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 31.42% |
| 10 | Revolution Medicines | 37.43 Bn | 37.43 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.71% |
| Dec 31, 2025 | -30.64% |
| Sep 30, 2025 | 8.13% |
| Jun 30, 2025 | -5.14% |
| Mar 31, 2025 | -4.47% |
| Dec 31, 2024 | -19.22% |
| Sep 30, 2024 | 14.18% |
| Jun 30, 2024 | -148.34% |
| Mar 31, 2024 | 13.35% |
| Dec 31, 2023 | -26.46% |
| Sep 30, 2023 | 18.76% |
| Jun 30, 2023 | 1.74% |
| Mar 31, 2023 | 2.51% |
| Dec 31, 2022 | 34.51% |
| Sep 30, 2022 | 42.65% |
| Jun 30, 2022 | 34.41% |
| Mar 31, 2022 | 42.77% |
| Dec 31, 2021 | 46.15% |
| Sep 30, 2021 | 34.39% |
| Jun 30, 2021 | -41.86% |